Market Place
Market Place
Post Enquiry
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Sales Forecast of FDA’s New Drug Approvals of 2017
2017 was a landmark
year for the pharmaceutical industries in the US and Europe, with a sharp
increa
Pfizer exits China venture with Hisun; FDA mulls more steps to increase generic drug competition
This week in Phispers, we look at the measures US FDA announced last week to increase competition in
Top drugs by sales in 2016: Who sold the blockbuster drugs?
The year 2016 finished with a whimper insofar as mergers and acquisitions (M&As) were concerned.
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
Sanofi’s rough week; Quality snags at Pfizer; FDA warns against commonly used drug
This week, Phispers delves into Pfizer’s acquisition of Medivation and its impact on Sanofi. T
FDA’s Drug Approvals in 2015: Novel Drugs & New Versions of Existing Drugs
Each year,
the US Food and Drug Administration (FDA) approve hundreds
of new medications. A small su
Next-gen aripiprazole pill that sends messages from the patient’s stomach
Wouldn’t it be great if your medicine could send a signal from your stomach to the clinic that
Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?
Over
700 commonly used generic medicines were
recommended for suspension by the European Medic
Teva and Otsuka’s Multi-Billion dollar plan when blockbusters turn Generic: Deuterium Chemistry
Two blockbusters,
Otsuka’s
Abilify® (aripiprazole)
and Teva’s
Copaxone® (glatir
